Results 211 to 220 of about 5,745,110 (281)
A Performance Management System in Healthcare for All Seasons? [PDF]
Vainieri M, Noto G, Ferre F, Rosella LC.
europepmc +1 more source
ABSTRACT Objective People with epilepsy (PWE) may experience cognitive deficits but fail to undergo formal evaluation. This study compares cognitive status between PWE and healthy controls in the West African Republic of Guinea. Methods A cross‐sectional, case–control study was conducted in sequential recruitment phases (July 2024–July 2025) at Ignace ...
Maya L. Mastick +14 more
wiley +1 more source
Reconsidering performance management to support innovative changes in health care services. [PDF]
Anders A.
europepmc +1 more source
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi +2 more
wiley +1 more source
The interplay between ethics, justice, corporate social responsibility, and performance management sustainability. [PDF]
Tziner A, Persoff M.
europepmc +1 more source
Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein +13 more
wiley +1 more source
Performance Management in the Virtual Workplace During the COVID-19 Pandemic and Beyond
Parisi L, Wang R, Ma R.
europepmc +1 more source
Performance management in primary healthcare: Nurses' experiences. [PDF]
Madlabana CZ, Petersen I.
europepmc +1 more source
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones +3 more
wiley +1 more source

